Merck & Co., Inc.

NYSE:MRK Stok Raporu

Piyasa değeri: US$320.0b

Merck Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

Merck şu anki getirisi 2.62% olan temettü ödeyen bir şirkettir. Bir sonraki ödeme tarihi olan 8th July, 2026 temettüden önceki tarihi 15th June, 2026 dir.

Anahtar bilgiler

2.6%

Temettü verimi

1.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi4.1%
Gelecekteki Temettü Verimi2.9%
Temettü Büyümesi6.5%
Bir sonraki temettü ödeme tarihi08 Jul 26
Eski temettü tarihi15 Jun 26
Hisse başına temettün/a
Ödeme oranı91%

Son temettü ve geri alım güncellemeleri

Recent updates

Seeking Alpha • Jul 02

Merck's Post-Keytruda Playbook Is Working, But Valuation Has Caught Up

Summary Merck & Co., Inc. is fairly valued after a strong YTD rally, with momentum in Keytruda and Winrevair driving raised guidance. Keytruda's patent cliff in 2028 remains a pivotal risk, but MRK is leveraging lifecycle management and pipeline assets to offset erosion. DCF modeling at 4% CAGR and 21% FCF margin supports a Hold rating for MRK stock, with intrinsic value resilient even under moderate downside scenarios. Execution on Winrevair, Keytruda Qlex, and the anti-TL1A IBD asset are critical for sustaining growth and valuation. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 30

MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple

Analysts have raised the Merck fair value estimate to $155 from $150, pointing to higher long term earnings expectations and multiple expansion, as reflected in recent Street price target increases to as high as $155. Analyst Commentary Recent Street research on Merck reflects a cluster of constructive views, with several bullish analysts lifting price targets and highlighting long term earnings potential.
Anlatı Güncellemesi • Jun 15

MRK: Terns Acquisition Execution And Bidding Risk Will Constrain Future Upside

Analysts have nudged their price targets for Merck higher by about $3 to $15 in recent research, supporting a modest increase in the fair value estimate to $101.68. This reflects updated profit margin assumptions and a slightly lower future P/E, along with adjustments to revenue growth expectations and discount rates.
Anlatı Güncellemesi • Jun 01

MRK: Oncology Pipeline And Terns Deal Will Shape Future Earnings Balance

Analysts have nudged their average price targets on Merck higher by $3 to $15 in recent weeks, citing updated views on the company’s oncology pipeline, the Terns Pharmaceuticals deal, and specific assets like Sac TMT that some expect could materially influence Merck’s long term earnings profile. Analyst Commentary Recent Street research around Merck clusters around two main themes, the potential of key pipeline assets like Sac TMT and TERN-701, and how recent study outcomes and deal activity could affect execution risk and valuation.
Anlatı Güncellemesi • May 21

Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026

Announcement Overview Analyst: Qudus Adebara (Founder, Wane Investment House) Merck & Co., Inc. (“Merck” or “the Company”), known as MSD outside the United States and Canada, has announced that it will present more than 100 abstracts spanning over 25 cancer types at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , scheduled for May 29 – June 2, 2026.
Anlatı Güncellemesi • May 19

Merck Completes Acquisition of Terns Pharmaceuticals

Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.
Anlatı Güncellemesi • May 17

MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance

Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.
Analiz Makalesi • May 11

Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture

Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...
Anlatı Güncellemesi • May 02

MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple

Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.
Anlatı Güncellemesi • Apr 19

Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)

Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.
Anlatı Güncellemesi • Apr 18

MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple

Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.
Anlatı Güncellemesi • Apr 04

MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside

Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.
Anlatı Güncellemesi • Mar 21

MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple

The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.
Anlatı Güncellemesi • Mar 06

MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside

Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.
Anlatı Güncellemesi • Feb 20

MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance

Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.
Anlatı Güncellemesi • Feb 06

MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple

Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.
Anlatı Güncellemesi • Jan 23

MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance

Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.
Anlatı Güncellemesi • Jan 09

MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes

Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.
Anlatı Güncellemesi • Dec 24

MRK: Cidara Flu Deal Will Likely Expose Overstated Long Term Expectations

Analysts have nudged their fair value estimate for Merck higher, lifting the price target by $1 to $83 as they factor in stronger revenue growth, improved profit margins, and a lower future P/E multiple supported by recent positive research initiations and deal activity. Analyst Commentary Street research around Merck has turned more constructive in recent weeks, with several firms highlighting an improving growth outlook and a more attractive risk reward profile.
Anlatı Güncellemesi • Dec 14

Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs

based on Q3 result
Anlatı Güncellemesi • Dec 10

MRK: Cidara Acquisition And Patent Overhang Will Shape Future Risk Reward Balance

Analysts have modestly raised their fair value estimate for Merck to approximately $106.62 from about $104.27 per share, citing the higher Street price target of $105, growing confidence in its infectious disease and oncology pipeline, and the view that shares remain attractively valued relative to the company's long term growth prospects. Analyst Commentary Street research on Merck continues to highlight a constructive long term outlook balanced by execution and concentration risks, with recent notes refining expectations around valuation, pipeline durability, and capital allocation.
Analiz Makalesi • Dec 02

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Merck & Co., Inc. ( NYSE:MRK ) will increase its dividend from last year's comparable payment on the 8th of January to...
Anlatı Güncellemesi • Nov 26

MRK: Recent Pipeline Deals And Patent Expiry Will Shape Outlook Ahead

Analysts have raised the price target for Merck to $105 from $98, citing stronger growth prospects and a more favorable valuation because of the company’s expanding pipeline and recent strategic deals. Analyst Commentary Recent analyst commentary on Merck highlights both positive momentum and notable risks that could influence the company’s trajectory in the months ahead.
Analiz Makalesi • Nov 02

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Merck & Co., Inc. ( NYSE:MRK ) came out with its quarterly results last week, and we wanted to see how the business is...

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MRK şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.

Büyüyen Temettü: MRK şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

Merck Piyasaya Karşı Temettü Getirisi
MRK temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (MRK)2.6%
Pazarın Alt %25'i (US)1.3%
Pazarın En İyi %25'i (US)4.1%
Sektör Ortalaması (Pharmaceuticals)1.9%
Analist tahmini (MRK) (3 yıla kadar)2.9%

Önemli Temettü: MRK 'in temettüsü ( 2.62% ), US piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.35% ) daha yüksektir.

Yüksek Temettü: MRK 'in temettüsü ( 2.62% ), US piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.12% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Yüksek ödeme oranı ( 91.4% ) nedeniyle MRK 'un temettü ödemeleri kazançlar tarafından yeterince karşılanmıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Makul nakit ödeme oranı ( 59.5% ) ile MRK 'un temettü ödemeleri nakit akışları ile karşılanmaktadır.

Güçlü temettü ödeyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/07/06 06:25
Gün Sonu Hisse Fiyatı2026/07/02 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Merck & Co., Inc. 49 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
David ToungArgus Research Company
Charles ButlerBarclays
Emily FieldBarclays